Table 2.
Radioligand | Type of binding study | Brain region | Result | Reference |
---|---|---|---|---|
[3H]spiperone | Homogenate | PFC 8, 9 | ↑ Bmax | Stanley and Mann 1983 (164) |
[3H]ketanserin | Homogenate | PFC 8, 9 | No change | Owen et al. 1983 (165) |
[3H]ketanserin | Homogenate | PFC 10 | No change | Crow et al. 1984 (166) |
[3H]ketanserin | Homogenate | Frontal cortex | No change | Owen et al. 1986 (167) |
[3H]spiperone | Homogenate | PFC 8, 9 | ↑ Bmax | Mann et al. 1986 (82) |
[3H]ketanserin | Homogenate | PFC 10 | No change | McKeith et al. 1987 (168) |
[3H]ketanserin | Homogenate | PFC 10, hippocampus | No change in PFC, ↓ in hippocampus |
Cheetaham et al. 1988 (169) |
[3H]spiperone | Homogenate | PFC 8, 9 | ↑ Bmax only in violent suicides |
Arora and Meltzer 1989 (170) |
[125I]LSD | Homogenate and sections |
PFC 9 | ↑ Bmax and ↑ in sections | Arango et al. 1990 (83) |
[3H]ketanserin | Homogenate and sections |
PFC, hippocampus | ↓ Bmax and ↓ in sections in PFC only |
Gross-Isseroff et al. 1990 (85) |
[3H]ketanserin | Sections | PFC 9 | ↑ mid-layers | Yates et al. 1990 (171) |
[3H]ketanserin | Homogenate | PFC 10 | ↑ Bmax | Laruelle et al. 1993 (172) |
[3H]ketanserin | Homogenate | PFC 9, amygdala | ↑ Bmax | Hrdina et al. 1993 (173) |
[125I]LSD | Sections | Temporal and entorhinal cortex, hippocampus |
No change | Joyce et al. 1993 (68) |
[3H]ketanserin | Homogenate | PFC 9, 10, 11 | No change in violent or nonviolent |
Arranz et al. 1994 (174) |
[3H]spiperone | Homogenate | PFC 10, hippocampus | No change | Lowther et al. 1994 (175) |
[3H]ketanserin | Sections | PFC 10, hippocampus | No change | Stockmeier et al. 1997 (176) |
[3H]ketanserin | Homogenate | PFC 8, 9 | ↑ Bmax | Turecki et al. 1999 (177) |
[3H]ketanserin | Homogenate | PFC 9, 10, 11, hippocampus |
No change in PFC, ↓ Bmax in hippocampus |
Rosel et al. 2000 (178) |
[3H]LSD | Homogenate | PFC 8, 9 | ↑ Bmax | Pandey et al. 2002 (23) |
PFC = prefrontal cortex; ↑ = increase; ↓ = decrease.